Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Biogen paid Ionis a US $ 60 million one-time upfront payment
Subscribe To Our Newsletter & Stay Updated